632 related articles for article (PubMed ID: 26619740)
1. [DRUG INDUCED EXANTHEMA AND SEVERE CUTANEOUS DRUG REACTIONS].
Bensaïd B; Valeyrie-Allanore L; Lebrun-Vignes B; Nicolas JF
Rev Prat; 2015 Sep; 65(7):981-5. PubMed ID: 26619740
[TBL] [Abstract][Full Text] [Related]
2. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
Darlenski R; Kazandjieva J; Tsankov N
Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
[TBL] [Abstract][Full Text] [Related]
3. Adverse cutaneous drug reactions in a single quaternary referral hospital.
Botelho LF; Porro AM; Enokihara MM; Tomimori J
Int J Dermatol; 2016 Apr; 55(4):e198-203. PubMed ID: 26710962
[TBL] [Abstract][Full Text] [Related]
4. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions.
Hassoun-Kheir N; Bergman R; Weltfriend S
Int J Dermatol; 2016 Nov; 55(11):1219-1224. PubMed ID: 27368159
[TBL] [Abstract][Full Text] [Related]
5. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
[No Abstract] [Full Text] [Related]
6. [Severe delayed drug hypersensitivity reactions].
Maniu CM; Buss G; Feldmeyer L; Spertini F; Ribi C
Rev Med Suisse; 2013 Apr; 9(382):803-4, 806-11. PubMed ID: 23667969
[TBL] [Abstract][Full Text] [Related]
7. Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression.
Weinborn M; Barbaud A; Truchetet F; Beurey P; Germain L; Cribier B
Int J Dermatol; 2016 Nov; 55(11):1225-1233. PubMed ID: 27421110
[TBL] [Abstract][Full Text] [Related]
8. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
[TBL] [Abstract][Full Text] [Related]
9. Delayed cutaneous manifestations of drug hypersensitivity.
Bircher AJ; Scherer K
Med Clin North Am; 2010 Jul; 94(4):711-25, x. PubMed ID: 20609859
[TBL] [Abstract][Full Text] [Related]
10. Annular drug eruptions.
Wu WH; Chu CY
Clin Dermatol; 2022; 40(5):450-465. PubMed ID: 34979270
[TBL] [Abstract][Full Text] [Related]
11. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E
J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
CEDEF
Ann Dermatol Venereol; 2018 Mar; 145 Suppl 1():S189-S200. PubMed ID: 29428446
[No Abstract] [Full Text] [Related]
13. [Adverse cutaneous drug reactions].
Rupec RA; Boneberger S; Ruzicka T
Dtsch Med Wochenschr; 2007 Dec; 132(50):2685-94. PubMed ID: 18058660
[No Abstract] [Full Text] [Related]
14. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
15. [Severe cutaneous drug reactions in children].
Mockenhaupt M
Hautarzt; 2017 Oct; 68(10):803-814. PubMed ID: 28932875
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
17. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
Viera MH; Perez OA; Patel JK; Jones I; Berman B
Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
[TBL] [Abstract][Full Text] [Related]
18. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
19. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity.
Hanafusa T; Azukizawa H; Matsumura S; Katayama I
J Dermatol Sci; 2012 Mar; 65(3):213-9. PubMed ID: 22226608
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat (Adenuric). Toxic epidermal necrolysis and severe hypersensitivity reactions added to the EU SPC.
Prescrire Int; 2015 Jun; 24(161):153. PubMed ID: 26436167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
